H.C. Wainwright raised the firm’s price target on CytomX Therapeutics (CTMX) to $17 from $10 and keeps a Buy rating on the shares, stating that the company sets a “new precedent for late-line colorectal cancer” with its Phase 1 expansion data for varsetatug masetecan. Varseta-M “already looks like a real 4L drug, with a credible path to 3L if optimized safety holds,” says the analyst, who is increasing the firm’s view on the probability of approval to 60% from 40%.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- Midday Fly By: Meta said to eye job cuts, Dollar Tree up after earnings
- CytomX Therapeutics upgraded to Overweight at JPMorgan after late-line CRC data
- CytomX Therapeutics upgraded to Overweight from Neutral at JPMorgan
- CytomX Therapeutics price target raised to $12 from $10 at Oppenheimer
- Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform